Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15
Stock Information for Relmada Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.